Significant Ownership of Affinity Asset Advisors, LLC
- Signature - Title
- /s/ Andrew Weinstein - Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
- Location
- New York, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Affinity Asset Advisors, LLC.
Follow Filing Activity
Follow Affinity Asset Advisors, LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of Affinity Asset Advisors, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IBIO | iBio, Inc. | Common Stock, par value $0.001 per share | 10% | $4,627,194 | +$424,252 | 2,401,616 | +10% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| NXTC | NextCure, Inc. | Common Stock, $0.001 par value per share | 10% | $4,375,018 | +$1,966,899 | 348,607 | +82% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| VTYX | Ventyx Bioscience, Inc. | Common Stock, $0.0001 par value per share | 9% | $58,381,906 | +$21,744,625 | 6,465,041 | +59% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| OVID | Ovid Therapeutics Inc. | Common Stock, par value $0.001 per share | 9% | $19,803,141 | 12,149,166 | 0% | Affinity Asset Advisors, LLC | 22 Jan 2026 | |
| STRO | Sutro Biopharma, Inc. | Common Stock, $0.001 par value per share | 8.8% | $8,444,817 | 748,382 | Affinity Asset Advisors, LLC | 22 Jan 2026 | ||
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, $0.0001 par value per share | 8.6% | $12,870,974 | +$7,880,460 | 1,713,092 | +158% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| STRO | SUTRO BIOPHARMA, INC. | Common Stock, par value $0.001 per share | 7.8% | $5,717,348 | 6,583,772 | Affinity Healthcare Fund, LP | 16 Oct 2025 | ||
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 7.1% | $51,813,451 | +$9,589,340 | 5,217,660 | +23% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 6.7% | $22,251,791 | -$731,169 | 834,964 | -3.2% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5.7% | $19,087,141 | +$814,240 | 1,051,054 | +4.5% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | Common Stock, $0.0001 par value per share | 5.5% | $7,346,762 | 884,172 | 0% | Affinity Asset Advisors, LLC | 22 Jan 2026 | |
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 2.9% | $2,203,898 | 1,867,710 | Affinity Healthcare Fund, LP | 20 May 2025 |
Schedules 13D/G Reported by Affinity Asset Advisors, LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.